Summary of matters needing attention when using Telisotuzumab

Telisotuzumab (Telisotuzumab) is a new type of targeted drug, mainly used to treat patients with tumors whose MET receptor tyrosine kinase is overexpressed or abnormally activated. It especially shows good therapeutic prospects in solid tumors such as non-small cell lung cancer (NSCLC). As an antibody conjugate (ADC), it specifically targets the monoclonal antibody to the MET receptor on the surface of tumor cells, while carrying cytotoxic drugs to accurately kill tumor cells. In order to ensure patient medication safety and therapeutic effect, the following aspects should be paid attention to when using terituzumab.

1. Preparation and evaluation before medication

Prior to initiating treatment with territuzumab, patients should undergo a comprehensive physical examination and relevant laboratory testing. Including liver and kidney function, blood routine, and electrocardiogram, etc., to evaluate whether the patient is suitable for such targeted therapy. In particular, it is necessary to confirm whether the expression level of MET receptors in the patient's tumor tissue meets the treatment indications. The MET status is usually confirmed through immunohistochemistry (IHC) or genetic testing to ensure accurate and effective drug targeting.

In addition, medical staff need to inquire in detail about the patient's allergy history and past medication history to check whether there is a risk of allergy to monoclonal antibodies or ADC components. For pregnant or lactating women, the risks of use should be carefully considered, a pregnancy test should be performed if necessary, and contraceptive measures should be informed.

2. Monitoring and management during medication use

Territuzumab is mostly administered by intravenous infusion, usually once every 2 to 3 weeks. The specific dose and interval are adjusted by the doctor based on the patient's weight, condition and tolerance. During medication, the patient's vital signs and infusion reactions need to be closely monitored to prevent allergies or infusion-related adverse reactions.

Clinically, common adverse reactions of territuzumab include fatigue, rash, abnormal liver function, gastrointestinal reactions, and hematological abnormalities. Patients should undergo regular blood routine and liver and kidney function tests to detect and deal with potential side effects in a timely manner. When serious adverse reactions are encountered, the medication should be suspended and corresponding symptomatic supportive treatment should be given. If necessary, the dose should be adjusted or treatment terminated.

In addition, because it contains cytotoxic drug ingredients, patients need to pay attention to personal hygiene to avoid the risk of infection. If you have symptoms such as fever, cough, diarrhea, etc., you should inform your doctor in time.

3. Precautions for special groups and combined medication

Elderly patients, patients with hepatic and renal insufficiency, and patients with heart disease need to be cautious when using terituzumab, and the dose may need to be adjusted or the dosing interval to be extended. Pregnant and lactating women should avoid use because the safety of the drug has not been determined.

For patients receiving other chemotherapy, targeted drugs, or immunotherapy concurrently, drug-drug interactions and cumulative toxicity risks should be strictly evaluated. Combined medication may increase the incidence of adverse reactions and needs to be adjusted under the guidance of a specialist.

4. Lifestyle and psychological support

During the treatment period, patients should maintain good living habits, eat properly, ensure adequate sleep, and avoid overwork and mood swings. Actively cooperate with regular follow-up visits and complete relevant examinations on time, which will help doctors grasp treatment progress and adjust plans in a timely manner.

Since cancer treatment may cause psychological stress, patients and their families should seek psychological support and professional help to enhance their confidence in overcoming the disease. At the same time, patients should maintain good communication with the medical team and provide timely feedback on their physical and mental status to ensure the smooth progress of treatment.

As a precisely targeted antibody-conjugated drug, terituzumab has broad clinical application prospects due to its efficient tumor killing ability and relatively controllable side effects. Correctly understanding and mastering the precautions for its use is crucial to ensuring patient safety and improving treatment effects. Patients should use medications in a standardized manner under the guidance of professional doctors, regularly monitor and actively respond to adverse reactions, and cooperate with scientific life management to ultimately achieve the best treatment effect and quality of life.

Reference materials:https://www.drugs.com/